{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:02:53Z","timestamp":1778889773558,"version":"3.51.4"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Plasmablastic lymphoma (PBL) is an aggressive and rare subtype of non\u2010Hodgkin lymphoma with no standard\u2010of\u2010care therapy. We reviewed all patients diagnosed with histologically confirmed PBL in British Columbia, Canada between 1997 and 2019. Overall, 42 patients were identified, including 15 (36%) positive for HIV and nine (21%) on chronic immunosuppression. Curative\u2010intent treatment consisting primarily of cyclophosphamide, doxorubicin, vincristine and prednisone was administered to 31 patients, of which 74% achieved response, however 61% relapsed after a median of 7.5\u00a0months. At a median follow\u2010up of eight years for the whole cohort, five\u2010year progression\u2010free survival (PFS) and overall survival (OS) were 18% [95% confidence interval (CI): 6%, 30%] and 22% (95% CI: 8%, 36%) with median eight and 15\u2009months respectively. There were no differences in relapse rate (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.962), PFS (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.228) or OS (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.340) according to immune status. For those treated with curative intent, five\u2010year PFS and OS were 24% (95% CI: 8%, 40%) and 31% (95% CI: 13%, 49%) with median 18 and 27\u2009months respectively. In this population\u2010based cohort of PBL patients spanning 20\u2009years, survival outcomes were poor. Ultimately, further research is needed to develop more effective treatment strategies and to improve survival for patients.<\/jats:p>","DOI":"10.1111\/bjh.18399","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T01:13:16Z","timestamp":1660353196000},"page":"230-238","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinicopathological characteristics and long\u2010term outcomes of plasmablastic lymphoma in British Columbia"],"prefix":"10.1111","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0066-917X","authenticated-orcid":false,"given":"Rehan","family":"Jessa","sequence":"first","affiliation":[{"name":"Faculty of Medicine University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Chien","sequence":"additional","affiliation":[{"name":"Leukemia\/Bone Marrow Transplant Program of BC and Division of Hematology BC Cancer, University of British Columbia  Vancouver British Columbia Canada"},{"name":"Department of Haematology Auckland City Hospital  Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-3009","authenticated-orcid":false,"given":"Diego","family":"Villa","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Division of Medical Oncology BC Cancer, University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Division of Medical Oncology BC Cancer, University of British Columbia  Vancouver British Columbia Canada"},{"name":"Department of Blood and Marrow Transplant and Cellular Immunotherapy Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham W.","family":"Slack","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine BC Cancer, University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9863","authenticated-orcid":false,"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Division of Medical Oncology BC Cancer, University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Division of Medical Oncology BC Cancer, University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-9765","authenticated-orcid":false,"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Division of Medical Oncology BC Cancer, University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin W.","family":"Song","sequence":"additional","affiliation":[{"name":"Leukemia\/Bone Marrow Transplant Program of BC and Division of Hematology BC Cancer, University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-1425","authenticated-orcid":false,"given":"Alina S.","family":"Gerrie","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Division of Medical Oncology BC Cancer, University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-567479"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25432"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134972"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25955"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000234"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0163-z"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.516040"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190801911662"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.271957"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153441"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25405-w"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw684"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15156"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.14740\/jh672"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835e069d"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S142814"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1658-3876(10)50050-5"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21250"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0304"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.09.020"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152603"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.06.009"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024498"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18399","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18399","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T12:53:34Z","timestamp":1692622414000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/bjh.18399"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18399","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"2022-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}